SPAGO Imaging has now confirmed that the relaxivity (t1)of our nanoparticles is reliably more than 50/mmol Gd/s (at 2 T) as compared to the marketed contrast agents hovering around 4/mmol Gd/s. The relaxivity determines how much the MRI images are enhanced. In combination with the large number of gadolinium ions in each particle this enables the long sought technique of MR targeting with a positive contrast agent suitable for use in humans. We have reason to believe this breakthrough will lead to spectacular images in the near future. We also believe this will translate to better clinical tumor diagnostics so we can help saving lives and reduce suffering.